Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Fda Inspections
  6. /
  7. Raritan Pharmaceuticals, Inc.
FDA Inspection
•Raritan Pharmaceuticals, Inc.•October 20, 2016

Raritan Pharmaceuticals, Inc. – FDA Inspection, Oct 20, 2016

Record Details

This FDA Inspection record concerns Raritan Pharmaceuticals, Inc., with an inspection on October 20, 2016, issued by the Center for Drug Evaluation and Research, covering drugs.

Company
Raritan Pharmaceuticals, Inc.
Inspection Date
October 20, 2016
Product Type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Barbara J. Wilimczyk-Macri
  • Esteban Beltran (Issuing Officer)
  • Gobiga Vanniyasingam (Company Rep)
  • James R. Birkenstamm (Issuing Officer)
View Company Profile

ID · 779fe977-f104-48a2-84ec-2f8ccae976e3

Inspection Facts

Official Action Indicated (OAI)

Significant objectionable conditions were found and regulatory or administrative action is recommended.

Inspection number
995165
FDA center
Human Drugs
Project area
Drug Quality Assurance
Outcome
Form 483 issued

FDA Citations

11
  1. 21 CFR 211.84(d)(1)Component identity verification
  2. 21 CFR 211.142(b)Storage under appropriate conditions
  3. 21 CFR 211.25(b)Supervisor Training/Education/Experience
  4. 21 CFR 211.160(b)Scientifically sound laboratory controls
  5. 21 CFR 211.142Written warehousing procedures established/followed
  6. 21 CFR 211.184(c)Individual inventory record
  7. 21 CFR 211.204Record information inclusions
  8. 21 CFR 211.165(a)Testing and release for distribution
  9. 21 CFR 211.105(b)Distinctive ID or code not recorded in batch record
  10. 21 CFR 211.22(a)Approve or reject components, products

Showing 10 of 11 citations.

Full citation text and observation details available on the Dashboard.

Other FDA inspections of Raritan Pharmaceuticals, Inc.

7
DateClassificationOfficeProject area
April 2, 2025OAINew Jersey District OfficeDrug Quality Assurance
January 8, 2018VAICenter for Drug Evaluation and ResearchDrug Quality Assurance
April 14, 2016VAICenter for Drug Evaluation and ResearchDrug Quality Assurance
September 19, 2012VAICenter for Drug Evaluation and ResearchDrug Quality Assurance
August 21, 2012VAICenter for Drug Evaluation and ResearchDrug Quality Assurance
View all 7 other inspections on the company page
Other documents for Raritan Pharmaceuticals, Inc.
  • FDA Inspection 1250227 - 2025-04-02
  • FDA Inspection 1037112 - 2018-01-08
  • FDA Inspection 969785 - 2016-04-14
  • FDA Inspection 799355 - 2012-09-19
  • FDA Inspection 798953 - 2012-08-21

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Raritan Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.